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Gastroparesis: Current Concepts and Management
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Delayed gastric emptying in the absence of mechanical 
obstruction is referred to as gastroparesis. Symptoms 
that are often attributed to gastroparesis include post-
prandial fullness, nausea, and vomiting. Although tests 
of gastric motor function may aid diagnostic labeling, 
their contribution to determining the treatment ap-
proach is often limited. Although clinical suspicion of 
gastroparesis warrants the exclusion of mechanical 
causes and serum electrolyte imbalances, followed by 
empirical treatment with a gastroprokinetic such as 
domperidone or metoclopramide, evidence that these 
drugs are effective for patients with gastroparesis is 
far from overwhelming. In refractory cases with severe 
weight loss, invasive therapeutics such as inserting a 
feeding jejunostomy tube, intrapyloric injection of botu-
linum toxin, surgical (partial) gastrectomy, and implant-
able gastric electrical stimulation are occasionally 
considered.  (Gut and Liver 2009;3:166-173)
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NORMAL GASTRIC MOTOR FUNCTION
  From an anatomical point of view, the stomach consists 
of the cardia, the fundus, the gastric body, the antrum 
and the pylorus. Functionally, the stomach consists of a 
proximal part and a distal part, with a sphincter muscle 
at both ends. The proximal stomach consists of the fun-
dus and the proximal part of the gastric corpus. The main 
function of the proximal stomach is to provide a reservoir 
to the meal. The distal part of the stomach consists of 
the distal part of the gastric corpus, the gastric antrum 
and the pylorus. Its main function is to grind and empty 
the meal from the stomach.
1
  Structures involved in the control of gastric motility are 
smooth muscle cells, interstitial cells of Cajal, enteric 
nerves and the vagus nerve. The muscle layers of the 
stomach comprise an outer longitudinal layer, and an in-
ner circular muscle layer. Originating from the gastro- 
esophageal junction, in the proximal stomach, near the 
lesser curvature, an intermediate oblique muscle layer is 
also present. The myenteric plexus is found between the 
circular and longitudinal muscle layers in the stomach. 
Cell bodies of intrinsic neurons are grouped in ganglia 
whose number increases toward the distal antrum. 
Although these neurons receive input from vagal and 
sympathetic extrinsic nerves, the gastric myenteric plexus 
has major functional autonomy.
  S m o o t h  m u s c l e  c e l l s  i n  t h e  p r o x i m a l  s t o m a c h  d o  n o t  
display electrical oscillatory activity and this part is char-
acterized by a tonic contractile activity. Smooth muscle 
cells in the distal part of the stomach are characterized by 
the presence of rhythmic electrical activity, so-called slow 
waves, and phasic contractile activity. Slow waves are os-
cillations of the membrane potential at a frequency of 3 
cycles per minute, that are triggered from an area in the 
corpus near the greater curvature, the so-called pacemaker 
region of the stomach. Slow waves are generated by the 
interstitial cells of Cajal, a specialized type of cell of mes-
odermal origin, located near the myenteric plexus, are the 
generators of the slow waves.
2 The slow waves determine 
the timing of gastric contractions. Action potential dis-
charge, triggered by neurotransmitter release from the 
myenteric plexus, occurs at the crest of a slow wave. 
Thus, the slow waves determine the maximal frequency 
of contractions and the number of spikes determines the 
strength of the contractions. Masaoka T, et al: Update on Gastroparesis   167
Fig. 1. Functional parts of sto-
mach and their disorders.
  In the fasting state, the proximal gastrointestinal tract 
displays the migrating motor complex (MMC), a cyclical 
motor pattern of the stomach and the small intestine.
3 
The MMC consists of three different phases. Phase I is 
characterized by the absence of contractile activity; phase 
II displays irregular contractile activity and phase III is a 
phase of intense contractions at maximal frequency (3 per 
minute in the stomach, 12 per minute in the duodenum), 
which is again followed by phase I.
  When food is ingested, the MMC is suppressed and, 
through the vagus nerve, upper gastrointestinal motility 
switches to the fed or postprandial pattern. During and 
after ingestion of a meal, a relaxation of the proximal 
stomach occurs, which provides the meal with a reservoir 
and enables a gastric volume increase without a rise in 
pressure.
4 This also allows the stomach to retain food 
and to allow passage to the duodenum at a rate that 
matches the duodenal absorptive capacity. Two phases 
can be distinguished in the gastric reservoir function, and 
both are vagally mediated. Immediately after deglutition, 
the lower esophageal sphincter and the proximal stomach 
relax to allow passage and storage of the food bolus. 
These enterogastric reflexes appear to be vagally medi-
ated, with evidence that fat-induced proximal gastric re-
l a x a t i o n  i s  m e d i a t e d  b y  n i t r i c  o x i d e .
5,6 This rapid in-
hibitory phenomenon of gastric motility is called receptive 
relaxation. During gastric filling by food ingestion, a long- 
lasting relaxation of the proximal stomach occurs which 
is called adaptive relaxation or gastric accommodation. 
  After ingestion of a meal, circular peristaltic waves move 
from the mid-corpus to the pylorus. In the antrum, these 
contractions will grind the food and mix it with gastric 
juices through retropulsion, to finally lead to propulsion 
and evacuation of small particles. The flow of chyme from 
the stomach to the duodenum is pulsatile and is de-
termined by the balance between the strength of antral 
contraction, the degree of pyloric relaxation, and the duo-
denal resistance. The pylorus is also involved in regu-
lation of flow to the small intestine, and helps to discrim-
inate fluid, viscous and solid gastric contents. When gas-
tric content is fluid, antral contractions occlude the lumen 
and liquid is easily transferred to the duodenum. In case 
of a more viscous or solid gastric content, contractions 
are not lumen-obliterating, and retropulsion to the prox-
imal stomach serves to mix and grind gastric contents. 
Duodenal contractions serve to delay further gastric emp-
tying when the duodenum is not empty.
  Disordered gastric motility occurs whenever the proc-
esses of interdigestive motility, gastric reservoir function 
or gastric emptying are not properly controlled. Impaired 
control of gastric accommodation may lead to defective 
reservoir function, inability to ingest large meals and 
weight loss.
7 Abnormally rapid gastric emptying may lead 
to duodenal caloric overload and dumping syndrome
8 
Abnormally delayed emptying leads a gastroparesis syn-
drome with prolonged gastric stasis and fermentation of 
food (Fig. 1).
9
DEFINITION AND PATHOGENESIS OF GASTRO-
PARESIS
  Delayed gastric emptying in the absence of mechanical 
obstruction is referred to as gastroparesis. Symptoms that 
are often attributed to gastroparesis include postprandial 
fullness, nausea, vomiting - especially when this occurs 
late postprandially, anorexia and weight loss. The dis-
tinction between functional dyspepsia (FD) with delayed 
gastric emptying and idiopathic gastroparesis has not 
been clearly defined. Hence, it has been proposed to use 
the term gastroparesis only when persistently and se-
verely delayed gastric emptying is found in the absence of 
mechanical obstruction.
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Table 1. Causes of Gastroparesis
  N e u r o g e n i c
   ㆍPostsurgical (esp. vagotomy with/without partial/
subtotal gastrectomy, etc.)
   ㆍDiabetes 
   ㆍMedication/Drugs 
   ㆍInfection (Trypanozoma cruzi, VZV, EBV) 
   ㆍNeurologic disorders (stroke, multiple sclerosis)
  M y o g e n i c 
   ㆍScleroderma/Polymyositis/SLE 
   ㆍProgressive muscular dystrophy 
   ㆍAmyloidosis 
  Other etiologies
   ㆍZollinger Ellison syndrome 
   ㆍGastritis/Peptic ulcer disease 
   ㆍAnorexia nervosa 
   ㆍEndocrine disorders (hypothyroidism, CRF)
   ㆍAbdominal radiation 
  I d i o p a t h i c 
  Women constitute the majority of patients with a fe-
male: male ratio of 4:1 and the mean age of onset is 34 
years. The reason for the sex ratio imbalance remains 
unknown. There is also evidence of a gender difference in 
solid and liquid emptying between men and women with 
female gastric emptying slower than men.
12 Soykan et al.
13 
reported that 62% of patients with idiopathic gastro-
paresis revealed a past history of physical or sexual abuse. 
However, in a cohort of FD patients, Geeraerts et al.
14 
found an association of a history of abuse with impaired 
accommodation and with hypersensitivity to gastric dis-
tention, but not with delayed gastric emptying. The asso-
ciation of abuse history and gastroparesis probably de-
serves further studies.
  Gastroparesis is the end result of neuromuscular failure 
or excessive inhibitory influence, or both, on the compo-
nents of the gastric emptying process. The most im-
portant pathophysiological abnormalities contributing to 
the gastroparesis syndrome include fundal hypomotility, 
antral hypomotility, gastric arrhythmia and lack of an-
tropyloroduodenal coordination. In addition, excessive 
negative feedback mechanisms may also further delay gas-
tric emptying rate. 
  Delayed gastric emptying may be caused by a variety of 
mechanical and non-mechanical causes. Table 1 summa-
rizes a number of causes of gastroparesis, subdivided ac-
cording to the putative underlying abnormality. A number 
of drugs such as anticholinergics, opioids, L-dopa, tricy-
clic antidepressants and phenothiazines may contribute to 
a slowing of gastric emptying. When drug effects are 
ruled out, the predominant causes of gastroparesis are 
idiopathic (33%), diabetes mellitus (24%) and post-surgi-
cal (19%).
15 Gastroparesis may complicate both type I 
and type II diabetes, with reported prevalences of up to 
75% of the patients, depending on the patients studied 
and on the definition of gastroparesis. Diabetic gastro-
paresis involves mainly solid meals and is often asso-
ciated with the presence of autonomic neuropathy. Poor 
glycemic control may also contribute to delayed emptying, 
which in its turn may also impair glycemic control. 
Vagotomy causes rapid emptying of liquids and delayed 
emptying of solids. However, after partial gastrectomy, a 
complex situation exists which may lead to gastric stasis 
or rapid emptying with dumping syndrome, or bile reflux 
gastritis and even small intestinal bacterial overgrowth. 
Gastroparesis may also occur in association with less fre-
quent disorders such as anorexia nervosa, renal failure, 
Parkinson’s disease and chronic intestinal pseudo-obstruc-
tion. In a subgroup of patients with gastroparesis, no un-
derlying cause is apparent, so their disorder is considered 
idiopathic. In some of these, an acute onset and the pres-
ence of viral antibodies suggest involvement of acute in-
fections in the pathogenesis of gastroparesis.
11,15
DIAGNOSIS
  Prior to any assessment of gastric motor activity or 
emptying rate, organic disease needs to be excluded. This 
is preferentially done by upper G.I. endoscopy and 
radiology. Whilst endoscopy is often normal in patients 
with delayed gastric emptying, in profound gastroparesis, 
endoscopy may reveal food debris remnants, so-called be-
zoar, in the stomach.
16 Laboratory tests should exclude 
abnormalities of ion balance, glycemia and thyroid func-
tion. As a next step, tests of gastric motor function can 
be considered. These are useful for diagnostic labelling, 
but whether they really contribute to determining treat-
m e n t  a p p r o a c h  h a s  b e e n  a  m a t t e r  o f  c o n t r o v e r s y .  I n  t h e  
absence of alarm symptoms or risk factors, the optimal 
indication and timing of additional examinations in pa-
tients with symptoms suggestive of gastroparesis have not 
been established. Many clinicians will use prokinetics 
without having established delayed emptying, and empty-
ing testing may be most appropriate in those with poor 
symptom response (see below).
  Radionuclide gastric emptying measurement is consid-
ered the gold standard method to assess gastric emptying 
rate.
17 Solid and liquid emptying can be assessed sepa-
rately or simultaneously. The solid and/or liquid meals 
are labeled with a (different) radio-isotope, usually 
99Tc 
or 
111In. A gamma-camera measures the number of counts 
in an investigator-determined region of interest (total, 
proximal or distal stomach, small intestine) for a certain 
time frame after ingestion of a meal. Mathematical proc-Masaoka T, et al: Update on Gastroparesis   169
essing involves corrections for distance to the camera and 
isotope decay, and curve fitting which allows calculating 
the half emptying time, the lag phase (period of delay af-
ter meal ingestion before emptying starts) and % of la-
beled meal retention at intervals up to four hours after 
ingestion. 
  Comparing gastric emptying results from different hos-
pitals has been hampered by lack of standarization of the 
radioisotope emptying meal.  In an international collabo-
rative study, the range of normality has been established 
for a low-fat egg beater meal, with  the gastric residual at 
4 hours providing the most accurate parameter for the 
detection of delayed gastric emptying, with a sensitivity of 
100 percent and specificity of 70 percent. In contrast, the 
two hour measurement was not useful for detecting de-
layed emptying (sensitivity 100 percent but specificity 20 
percent).
18 Although not routinely applied, the radio-
isotope technique also has the ability to provide infor-
mation on distribution within the stomach.
19 Disadvantages 
include the use of radioactive substances, considerable 
costs and the poor level of standardization of meal com-
position and measuring times over different laboratories. 
  Another way of assessing the gastric emptying rate is a 
gastric emptying breath test. The solid or liquid phase of 
a meal is labeled with a 
13C containing substrate 
(octanoic acid, acetic acid, glycin or spirulina).
20 As soon 
as the labeled food enters the duodenum, absorption oc-
curs with generation of 
13CO2 which appears in the 
breath.
20 Breath sampling at regular intervals and mathe-
matical processing of its 
13CO2 content over time allows 
calculating a gastric emptying curve. The advantages of 
this test are the use of non-radioactive materials and the 
ability to perform the test outside a hospital setting. 
Several studies have shown that 
13C acid breath tests are 
valid alternatives for scintigraphy, given its safety and 
highly significant correlation with scintigraphy.
21,22 
Disadvantages are the absence of standardization of meal 
and substrate, and the absence of anatomical details. 
  Ultrasound has been used to measure the diameter of 
the gastric antrum as a marker of the emptying rate of a 
liquid meal.
17 The advantages of real-time ultrasound are 
its non-invasive nature and wide availability.  However, 
the ultrasound technique is time-consuming and not suit-
able for solid meals. It generally measures liquid meals 
only and liquid emptying rate is often preserved until gas-
troparesis is well advanced, and may be paradoxically en-
hanced under some conditions.
  In 1992 it was already reported that magnetic reso-
nance imaging (MRI) was a valid method for measuring 
gastric emptying in comparison to scintigraphy.
23 Recent 
data confirm these findings,
24 but the limited availability 
and high costs of MRI limit the use in daily practice. 
Moreover, MRI is usually done in the less physiological 
supine position.
MEDICAL THERAPY
  The long term prognosis of gastroparesis has not been 
well studied. One study in 20 patients with diabetic gas-
troparesis found no change in gastric emptying rates after 
a 12 year follow-up.
25 Hence, in most patients presenting 
with important symptoms, therapeutic measures will be 
necessary.
1. Dietary measures
  In case of gastroparesis, dietary interventions consisting 
of smaller more frequent meals throughout the day with 
restricted fat content are often proposed. Meals of larger 
weight and kcal are associated with longer emptying 
times.
26 Fat intake releases cholecystokinin which can fur-
ther delay gastric emptying. However, the efficacy of these 
measures has not been established, and most patients 
have already implemented these on their own initiative. 
In addition, patients can be advised to use liquid nu-
trients as a larger part of the daily food intake. Finally, 
low-fibre meals are advised to prevent bezoar formation.  
In patients with diabetic gastroparesis, additional meas-
u r e s  a r e  t a k e n  t o  o p t i m a l i s e  g l y c e m i c  c o n t r o l .  T h e  e f f e c t  
of better glycemic control on gastroparesis is not fully 
proven, but it is known that acute hyperglycaemia slows 
gastric emptying
27 and attenuates the efficacy of proki-
netic drugs.
28,29
2. Prokinetic drugs
  S e v e r a l  p r o k i n e t i c  a g e n t s  h a v e  b e e n  s h o w n  t o  e n h a n c e  
gastric emptying rate in patients with idiopathic or dia-
betic gastroparesis (Table 2). The underlying assumption 
is that these drugs, through enhancement of delayed gas-
tric emptying, should improve symptoms. However, stud-
ies available so far fail to convincingly prove this hypoth-
esis and evidence that the symptomatic improvement is 
related to enhancement of gastric emptying is lacking.
30-33 
For diabetic gastroparesis, several studies have reported 
improvement of gastric emptying with prokinetic drugs, 
b u t  n o  c o n s i s t e n t  e f f e c t s  o n  s y m p t o m s  o r  g l y c e m i c  c o n -
trol were obtained.
34,35
  The best studied prokinetics are metoclopramide, dom-
peridone, cisapride and erythromycin. Clinical suspicion 
of gastroparesis warrants ruling out of mechanical causes 
and serum electrolyte imbalances, followed by empirical 
treatment with a gastroprokinetic like domperidone or 
metoclopramide.
11,15,36 Metoclopramide is a dopamine antag-170   Gut and Liver, Vol. 3, No. 3, September 2009
Table 2. Overview of Prokinetic Drugs
Receptor affinities
Antiemetic 
properties
Gastric emptying Visceral sensitivity
Fundic 
accommodation
  Metoclopramide D2 antagonist + ↑↓
5HT4 agonist
  D o m p e r i d o n e D 2 antagonist + ↑↓
  C i s a p r i d e 5 H T 4 agonist ↑↑
5HT3 antagonist
  Erythromycin Motilin receptor agonist ↑↓
  T e g a s e r o d 5 H T 4 agonist ↑↑
  I t o p r i d e D 2 antagonist + ↑↓
Cholinesterase inhibitor
  M o s a p r i d e 5 H T 4 agonist ↑
5HT3 antagonist
  Levosulpiride D2 antagonist + ↑↓
5HT4 agonist
onist with both central and peripheral activity. It is avail-
able for both oral and parenteral use. Besides its anti-em-
etic effect it has some prokinetic activity. Because of its 
CNS side effects, high-dose oral metoclopramide is not 
advised for long term use. The parenteral form can be 
useful in the acute phase, when no oral intake is possible. 
Domperidone is a dopamine antagonist with only peripheral 
activity.  Domperidone is the drug of choice as metoclopra-
mide may be associated with extrapyramidal side effects. 
Both metoclopramide and domperidone can cause 
hyperprolactinemia.  Cisapride facilitates acetylcholine re-
lease from myenteric neurons through a 5-HT4 receptor 
mediated effect.
37 Superior efficacy and tolerance has been 
suggested for domperidone over metoclopramide,
38,39 and 
for cisapride over metoclopramide.
40 However, due to en-
hanced risk of QT prolongation with cardiac arrhythmia’s, 
cisapride is no longer available for use in routine clinical 
practice.
41 There are only anecdotal reports supporting the 
efficacy of other prokinetic approaches such as mosapride, 
renzapride, levosulpiride, and clonidine in diabetic gastro-
paresis.
36
  Erythromycin act as a motilin receptor agonist and has 
prokinetic properties, available for both i.v and p.o. use. 
Short term studies in diabetic and postsurgical gastro-
paresis have reported beneficial effects of treatment with 
erythromycin (3×250-500 mg).
42 I t  i s  t h e  m o s t  p o t e n t  
gastric prokinetic with major improvement in gastric 
emptying. Due to its antibiotic properties long term use 
can lead to the induction of resistant strains. There are 
other possible side effects like ototoxicity and pseudo-
membranic colitis, which limits long-term use in patients 
with gastroparesis. Furthermore, the problem of tachy-
phylaxis makes long term use less attractive. In a liter-
ature review, Maganti et al. concluded that, although er-
ythromycin was proven to be a strong prokinetic, the 
available studies do not establish efficacy of erythromycin 
in relieving symptoms of gastroparesis.
43 Studies with a 
related macrolide compound, ABT-229, failed to demon-
strate any symptomatic benefit of this non-antibiotic mac-
rolide prokinetic in idiopathic and diabetic gastroparesis.
44,45
    Overall, the evidence that classical gastroprokinetics 
like metoclopramide, domperidone, cisapride or eryth-
romycin are effective in gastroparesis is far from over-
whelming.
32 Several newer gastroprokinetics have been 
evaluated or are under evaluation.
36 These include other 
5-HT4 agonists such as renzapride, tegaserod or TD-5108, 
newer macrolide compounds such as mitemcinal, and 
ghrelin receptor agonists such as TZP-101.
36 None of 
these is presently commercially available.
INVASIVE THERAPEUTIC MODALITIES
  In refractory cases with severe weight loss, invasive 
therapies like insertion of a feeding jejunostomy tube,
11 
intrapyloric injection of botulinum toxin, surgical (partial) 
gastrectomy or implantable gastric electrical stimulation 
(GES) are occasionally considered. Home parenteral nu-
trition is another option, but unlike enteral tube feeding, 
this is not devoid of potentially life-threatening complica-
tions like septicaemia or thrombo-embolism. The efficacy 
of these modalities has not been clearly established. A 
feeding jejunostomy is more frequently used to maintain 
hydration, nutrition and glycemic control. The available 
studies assessed symptom improvement through sub-
jective reporting of symptoms in diabetic patients with 
gastroparesis. Although symptoms seemed to improve, 
the evidence is not substantial. Moreover, jejunostomy is 
associated with a high complication rate, requiring hospi-
t a l i z a t i o n  o r  s u r g e r y  i n  m o r e  t h a n  h a l f  o f  t h e  c a s e s .
46-48 
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transmission.  Injection of the toxin directly in the pyloric 
sphincter has the potential to reduce gastric outlet resist-
ance and thereby improve gastric emptying and symptoms 
associated with delayed gastric emptying. Anecdotal evi-
dence suggests the use of intrapyloric injection of botu-
linum toxin in idiopathic or diabetic gastroparesis,
49-51 but 
in two controlled studies, no benefit over saline injection 
was found.
52,53
  Especially for surgical therapy, supportive evidence of 
good quality is not available. Only few studies assessed 
symptom improvement in a standardized way, and most 
studies focused mainly on technical aspects. Extensive 
subtotal or completion gastrectomy seems to be the most 
advocated surgical option for patients with refractory, 
postsurgical gastroparesis. Symptom improvements are 
claimed in 67 to 100% of patients, but without a benefi-
cial effect in terms of weight gain.
54 A venting gastro-
stomy was reported to reduce symptoms and improve nu-
tritional status,
55 but no other study confirmed this 
experience. Completion of gastrectomy for severe post-
gastrectomy stasis is successful in 43% of patients. The 
combination of nausea, need for total parenteral nutrition 
and retained food at endoscopy are negative prognostic 
factors.
54,56
  In the light of the unsatisfactory results from conven-
tional medical therapy, the development of implantable 
GES devices, which received Food and Drug Administration 
approval as a humanitarian device exemption in March 
2000 (Enterra, Medtronics), provides a potentially attrac-
tive alternative for the medical or surgical treatment of 
difficult gastroparesis. The gastric stimulation device is 
implanted subcutaneously in the abdominal wall and the 
electrodes are placed in the smooth muscle along the 
greater curvature.  The stimulator delivers electrical puls-
es at 12 cpm. To date, beneficial effects of GES that have 
been reported from uncontrolled case series include im-
provement in nutritional status, symptoms of nausea and 
vomiting as well as improved quality of life.
57 Only one 
randomized double blind cross over trial with GES; the 
WAVESS-trial was reported. Unfortunately, the published 
results and the results presented to the US FDA are 
discrepant.
58 In one-month blinded controlled phase with 
the device off or on, vomiting frequency was significantly 
reduced during the month when the device was in the 
‘ON’ mode compared to the ‘OFF’ mode. In a longer 
open label phase, symptom scores and quality of life were 
significantly improved up to 12 months after the start of 
gastric stimulation. The gastric emptying rate, in contrary, 
was not significantly accelerated and there was no correla-
tion between the improvement in symptom score and gas-
tric emptying rate.
59 To date, the mechanism underlying 
the symptomatic improvement has not been established, 
and favourable results on symptoms of vomiting seem to 
occur regardless of whether gastric emptying was delayed 
or normal.
60 Although some longer-follow up series have 
been published, it remains unclear whether the long-term 
efficacy of this modality is superior to the natural history 
of severe gastroparesis.
61 Uncontrolled data suggest im-
provement of symptoms and reduced HbA1C-levels in pa-
tients with diabetic gastroparesis.
62,63 Hence, it is at pres-
ent unclear whether this is really a treatment for gastro-
paresis, or mainly symptomatic therapy for nausea and 
vomiting. Given the high cost, and paucity of available da-
ta, generalised use of the device cannot be recommended 
and patients should undergo gastric electrical stimulation 
treatment only in the setting of a research protocol.
61
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